RGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Repligen Corp (RGEN) is not a strong buy at the current pre-market price of $133.65 for a beginner investor with a long-term focus. While the company has shown revenue growth and positive guidance, declining net income and EPS, insider selling, and neutral technical indicators suggest caution. The absence of strong trading signals and recent congressional trading data further supports a hold recommendation.
The MACD histogram is -0.0533, below 0, and is negatively contracting, indicating bearish momentum. RSI is at 33.967, in the neutral zone, showing no clear signal. Moving averages are converging, and the stock is trading near its pivot level of 131.962, with resistance at 139.888 and support at 124.035. Overall, the technical indicators suggest a neutral trend.
Repligen reported strong Q4 revenue growth of 18% YoY and provided optimistic 2026 revenue guidance of $810M-$840M. Analysts maintain positive ratings, with price targets ranging from $170 to $195, reflecting confidence in the company's long-term potential.
Net income and EPS have significantly declined YoY, with net income down -139.23% and EPS down -138.33%. Insider selling has increased by 143.49% over the last month, raising concerns about internal confidence. Additionally, the broader market sentiment is negative, as indicated by the S&P 500's pre-market decline of -0.55%.
In Q4 2025, Repligen achieved revenue growth of 18.12% YoY, reaching $198M. However, net income dropped significantly by -139.23% YoY to $13.29M, and EPS declined by -138.33% to $0.23. Gross margin improved to 52.46%, up 9.45% YoY, reflecting operational efficiency despite profitability challenges.
Analysts remain optimistic about Repligen, with recent price targets ranging from $170 to $195 and ratings such as Outperform, Buy, and Overweight. However, most firms have slightly lowered their price targets, reflecting cautious optimism. Analysts highlight the company's strong Q4 performance and conservative guidance, which leaves room for potential upside.
